Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.22
(9.5%)
SEK 0.22
(9.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -42.22 Million SEK | -7.41% |
| 2022 | -39.3 Million SEK | -0.6% |
| 2021 | -39.07 Million SEK | -106.71% |
| 2020 | -18.9 Million SEK | 6.79% |
| 2019 | -20.28 Million SEK | -82.83% |
| 2018 | -11.09 Million SEK | -17.29% |
| 2017 | -9.45 Million SEK | -25.42% |
| 2016 | -7.54 Million SEK | -11.03% |
| 2015 | -6.79 Million SEK | -10.76% |
| 2014 | -6.13 Million SEK | -17.59% |
| 2013 | -5.21 Million SEK | -12.98% |
| 2012 | -4.61 Million SEK | -545.45% |
| 2011 | -715 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -7.76 Million SEK | 17.56% |
| 2024 Q2 | -8.15 Million SEK | -5.01% |
| 2023 Q2 | -7.86 Million SEK | 44.34% |
| 2023 Q3 | -7.11 Million SEK | 9.57% |
| 2023 FY | -42.22 Million SEK | -7.41% |
| 2023 Q4 | -9.41 Million SEK | -32.39% |
| 2023 Q1 | -14.13 Million SEK | -24.29% |
| 2022 FY | -39.3 Million SEK | -0.6% |
| 2022 Q1 | -9.85 Million SEK | 12.71% |
| 2022 Q4 | -11.36 Million SEK | -33.24% |
| 2022 Q3 | -8.53 Million SEK | 10.64% |
| 2022 Q2 | -9.54 Million SEK | 3.13% |
| 2021 Q3 | -10.1 Million SEK | 12.96% |
| 2021 Q1 | -6.06 Million SEK | -31.23% |
| 2021 Q4 | -11.29 Million SEK | -11.78% |
| 2021 Q2 | -11.6 Million SEK | -91.28% |
| 2021 FY | -39.07 Million SEK | -106.71% |
| 2020 FY | -18.9 Million SEK | 6.79% |
| 2020 Q1 | -5.05 Million SEK | 15.14% |
| 2020 Q2 | -4.76 Million SEK | 5.74% |
| 2020 Q3 | -4.48 Million SEK | 5.86% |
| 2020 Q4 | -4.62 Million SEK | -3.1% |
| 2019 Q2 | -4.54 Million SEK | 1.43% |
| 2019 Q4 | -5.95 Million SEK | -16.9% |
| 2019 Q3 | -5.09 Million SEK | -12.05% |
| 2019 FY | -20.28 Million SEK | -82.83% |
| 2019 Q1 | -4.61 Million SEK | -39.58% |
| 2018 Q1 | -2.45 Million SEK | 16.55% |
| 2018 Q3 | -2.24 Million SEK | 27.5% |
| 2018 Q4 | -3.3 Million SEK | -47.48% |
| 2018 FY | -11.09 Million SEK | -17.29% |
| 2018 Q2 | -3.09 Million SEK | -25.86% |
| 2017 Q3 | -1.97 Million SEK | 21.92% |
| 2017 Q4 | -2.94 Million SEK | -48.86% |
| 2017 FY | -9.45 Million SEK | -25.42% |
| 2017 Q1 | -2 Million SEK | -11.27% |
| 2017 Q2 | -2.53 Million SEK | -26.28% |
| 2016 Q1 | -2.24 Million SEK | -80.35% |
| 2016 FY | -7.54 Million SEK | -11.03% |
| 2016 Q4 | -1.8 Million SEK | -35.69% |
| 2016 Q3 | -1.32 Million SEK | 38.55% |
| 2016 Q2 | -2.16 Million SEK | 3.91% |
| 2015 Q3 | -1.38 Million SEK | 30.5% |
| 2015 Q2 | -1.99 Million SEK | 8.1% |
| 2015 Q1 | -2.17 Million SEK | -2.69% |
| 2015 Q4 | -1.24 Million SEK | 10.16% |
| 2015 FY | -6.79 Million SEK | -10.76% |
| 2014 FY | -6.13 Million SEK | -17.59% |
| 2014 Q4 | -2.11 Million SEK | -119.5% |
| 2014 Q3 | -964 Thousand SEK | 47.58% |
| 2014 Q2 | -1.83 Million SEK | -51.73% |
| 2014 Q1 | -1.21 Million SEK | 53.63% |
| 2013 Q1 | -1.37 Million SEK | -11.22% |
| 2013 Q3 | -1.02 Million SEK | -419.8% |
| 2013 Q4 | -2.61 Million SEK | -155.27% |
| 2013 FY | -5.21 Million SEK | -12.98% |
| 2013 Q2 | -197 Thousand SEK | 85.7% |
| 2012 FY | -4.61 Million SEK | -545.45% |
| 2012 Q4 | -1.23 Million SEK | -9.26% |
| 2012 Q2 | -1.38 Million SEK | -62.3% |
| 2012 Q3 | -1.13 Million SEK | 18.18% |
| 2012 Q1 | -854 Thousand SEK | 0.0% |
| 2011 FY | -715 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -156.208% |
| Amniotics AB (publ) | -30.87 Million SEK | -36.777% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -229.147% |
| BioArctic AB (publ) | 229.24 Million SEK | 118.418% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 90.943% |
| Genovis AB (publ.) | 61.5 Million SEK | 168.655% |
| LIDDS AB (publ) | -40.2 Million SEK | -5.017% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 446.972% |
| OncoZenge AB (publ) | -15.9 Million SEK | -165.52% |
| Saniona AB (publ) | -95.81 Million SEK | 55.93% |
| Simris Alg AB (publ) | -37.3 Million SEK | -13.183% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 86.421% |
| AcouSort AB (publ) | -17.08 Million SEK | -147.077% |
| Active Biotech AB (publ) | -45.8 Million SEK | 7.81% |
| Camurus AB (publ) | 431.44 Million SEK | 109.786% |
| Cantargia AB (publ) | -280.02 Million SEK | 84.922% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -100.194% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 62.741% |
| Mendus AB (publ) | -101.61 Million SEK | 58.45% |
| Kancera AB (publ) | -64.88 Million SEK | 34.93% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 883.94% |
| Lipum AB (publ) | -37.17 Million SEK | -13.57% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -248.145% |
| NextCell Pharma AB | -41.95 Million SEK | -0.627% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 89.123% |
| Xintela AB (publ) | -54.08 Million SEK | 21.929% |
| Ziccum AB (publ) | -21.41 Million SEK | -97.193% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -157.489% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -135.922% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -13.898% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 76.499% |
| CombiGene AB (publ) | -35.66 Million SEK | -18.386% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 72.194% |
| Intervacc AB (publ) | -102.85 Million SEK | 58.948% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 83.015% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -9539.954% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -155.541% |
| Corline Biomedical AB | -1.8 Million SEK | -2234.052% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 76.258% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 25.691% |
| Aptahem AB (publ) | -11.11 Million SEK | -279.947% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 65.691% |
| Fluicell AB (publ) | -26.55 Million SEK | -59.008% |
| Biovica International AB (publ) | -124.82 Million SEK | 66.174% |
| Abliva AB (publ) | -95.5 Million SEK | 55.792% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 87.084% |
| 2cureX AB (publ) | -32.51 Million SEK | -29.845% |
| I-Tech AB | 20.2 Million SEK | 308.994% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 94.923% |
| Cyxone AB (publ) | -22.98 Million SEK | -83.666% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 53.805% |
| Biosergen AB | -27.03 Million SEK | -56.167% |
| Nanologica AB (publ) | -75.15 Million SEK | 43.82% |
| SynAct Pharma AB | -215.81 Million SEK | 80.435% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 4.156% |
| BioInvent International AB (publ) | -330.3 Million SEK | 87.217% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -77.878% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 83.051% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -325.206% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 61.365% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -261.56% |